Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
27 studies found for:    United States, Indiana | Community Regional Cancer Care
Show Display Options
Download search resultsDownload the search results for:
United States, Indiana | Community Regional Cancer Care (27 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Conditions: Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Drug: fulvestrant;   Other: placebo;   Other: laboratory biomarker analysis
2 Active, not recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
3 Recruiting Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
4 Active, not recruiting Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Cognitive/Functional Effects
Interventions: Drug: temozolomide;   Biological: bevacizumab;   Other: placebo;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Procedure: dynamic susceptibility contrast-enhanced magnetic resonance imaging;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
5 Active, not recruiting Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Condition: Breast Cancer
Interventions: Radiation: Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy;   Radiation: Higher per daily radiation therapy;   Radiation: Concurrent boost radiotherapy;   Radiation: Standard per daily radiation therapy;   Radiation: Sequential boost radiotherapy
6 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
7 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
8 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
9 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
10 Unknown  Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer
Conditions: Depression;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: management of therapy complications;   Procedure: pain therapy;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
11 Active, not recruiting High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Conditions: Lung Cancer;   Radiation Toxicity
Interventions: Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy
12 Recruiting Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Conditions: Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions: Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
13 Active, not recruiting Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Conditions: Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
14 Active, not recruiting Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Conditions: Head and Neck Cancer;   Precancerous Condition
Interventions: Biological: cetuximab;   Drug: cisplatin
15 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
16 Active, not recruiting Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
17 Active, not recruiting Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Other: Placebo
18 Withdrawn Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
Conditions: Stage III Adult Soft Tissue Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage IVA Adult Soft Tissue Sarcoma;   Stage IIB Adult Soft Tissue Sarcoma;   Stage IIC Adult Soft Tissue Sarcoma
Interventions: Drug: doxorubicin;   Drug: filgrastim;   Drug: ifosfamide;   Procedure: biological response modifier therapy;   Procedure: brachytherapy;   Procedure: chemotherapy;   Procedure: colony-stimulating factor therapy;   Procedure: conventional surgery;   Procedure: cytokine therapy;   Procedure: intraoperative radiotherapy;   Procedure: radiation therapy;   Procedure: surgery
19 Active, not recruiting Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord
Condition: Head and Neck Cancer
Intervention: Radiation: radiation therapy
20 Active, not recruiting Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: flutamide;   Drug: releasing hormone agonist therapy;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years